BrightGene Bio-Medical of Suzhou said the Shanghai Stock Exchange has accepted its filing for a STAR Board IPO. The company expects to raise $50 million in the offering. BrightGene focuses on innovative drugs along with difficult-to-make generic drug APIs and finished drugs. It is developing immunoncology treatments and orally available GLP-1RA peptides for type 2 diabetes. Earlier this year, BrightGene completed an $80 million pre-IPO funding led by Sequoia China. More details....
Share this with colleagues:
Original Article: BrightGene Plans $50 Million Shanghai STAR Board IPO